Xilio Therapeutics, Inc. (XLO)

$2.5

-0.11 (-4.21%)
Rating:
Recommendation:
-
Symbol XLO
Price $2.5
Beta 0.000
Volume Avg. 0.09M
Market Cap 68.679M
Shares () -
52 Week Range 2.04-27.95
1y Target Est -
DCF Unlevered XLO DCF ->
DCF Levered XLO LDCF ->
ROE -333.00% Strong Sell
ROA -39.76% Strong Sell
Operating Margin -
Debt / Equity 18.20% Neutral
P/E -
P/B 0.41 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Healthcare
Biotechnology
NASDAQ Global Select

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.